Abbott Laboratories stock: TD Cowen sets a USD 135.00 target for Abbott Laboratories stock
Published on 10/16/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and upcoming results
- TD Cowen set a USD 135.00 target for Abbott Laboratories on October 16, 2026.
- Analysts expect USD 13.00 billion in third-quarter revenue and USD 1.42 earnings per share on October 21, 2026.
- Abbott Laboratories stock costs EUR 93.33 at Lang & Schwarz on October 16, 2026 at 4:32 p.m. CEST, minus 0.12 percent versus the Xetra close of October 15, 2026.
- Abbott Laboratories had a P/E ratio of 33.75 and a market capitalization of EUR 162.3 billion on October 16, 2026.
TD Cowen reissued a Buy rating for Abbott Laboratories and set a USD 135.00 target on October 16, 2026, according to MarketBeat. The target was 28.68 percent above Abbott Laboratories' USD 104.91 price on the NYSE at 10:37 a.m. ET, while the euro quote was EUR 93.33 at Lang & Schwarz on October 16, 2026 at 4:32 p.m. CEST, minus 0.12 percent versus the Xetra close of October 15, 2026 at EUR 93.44.
October 21 results carry estimates
Abbott Laboratories is expected to report third-quarter results before the US market opens on October 21, 2026, according to MarketBeat. Analysts cited by the outlet project USD 13.00 billion in revenue and USD 1.42 in earnings per share, against company guidance of USD 1.38 to USD 1.46 for earnings per share.
Euro quote stays below its high
The Xetra-linked euro quote sits within a 52-week range of EUR 70.10 to EUR 113.52. At EUR 93.33, Abbott Laboratories stock is 17.79 percent below that high, giving the price position more weight than the small daily move.
Valuation and reporting date
Abbott Laboratories had a market capitalization of EUR 162.3 billion and a P/E ratio of 33.75 on October 16, 2026. Its trailing dividend yield was 0.02 percent. The October 21 report is the next dated company event, with consensus centered on USD 13.00 billion in revenue and USD 1.42 in earnings per share.
Comparison with peers
Abbott Laboratories: minus 0.12 percent, P/E 33.75, market capitalization EUR 162.3 billion
Medtronic (NYSE, USD): minus 0.01 percent, P/E 23.50, market capitalization USD 122.1 billion
Stryker (NYSE, USD): plus 1.01 percent, P/E 30.69, market capitalization USD 113.6 billion
Trading level in euros
Abbott Laboratories was trading at EUR 93.33 at Lang & Schwarz on October 16, 2026 at 4:32 p.m. CEST, minus 0.12 percent versus the Xetra close of October 15, 2026 at EUR 93.44. The quote remains below its 52-week high while TD Cowen's USD 135.00 target provides a separate analyst reference.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories market data
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 16, 2026, 4:32 p.m. CEST): EUR 93.33
- Change versus Xetra close: minus 0.12 percent
- Xetra close (October 15, 2026): EUR 93.44
- Market capitalization: EUR 162.3 billion (as of October 16, 2026)
- 52-week range: EUR 70.10-113.52 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: October 21, 2026
Market context: Market report S&P 500.
